Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$2.5B |
| 2 |
Apple
AAPL
|
+$1.68B |
| 3 |
Tesla
TSLA
|
+$951M |
| 4 |
Johnson & Johnson
JNJ
|
+$750M |
| 5 |
UnitedHealth
UNH
|
+$703M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CTXS
Citrix Systems Inc
CTXS
|
+$913M |
| 2 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$257M |
| 3 |
NVIDIA
NVDA
|
+$225M |
| 4 |
Vertiv
VRT
|
+$164M |
| 5 |
JPMorgan Chase
JPM
|
+$161M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 12.48% |
| 2 | Healthcare | 7.36% |
| 3 | Financials | 6.5% |
| 4 | Consumer Discretionary | 5.35% |
| 5 | Industrials | 3.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3876
PubMatic
PUBM
$585M
| $149K | ﹤0.01% |
11,596
+9,786
| +541% | +$153K |
|
3877
HUTCHMED
HCM
$1.93B
| $148K | ﹤0.01% |
10,035
-60,165
| -86% | -$658K |
|
3878
Kinetik
KNTK
$3.72B
| $147K | ﹤0.01% |
4,452
+1,141
| +34% | +$38.9K |
|
|
SMC
3879
Summit Midstream
SMC
$426M
| $147K | ﹤0.01% |
8,826
| – | – |
|
|
IAUX
3880
i-80 Gold Corp
IAUX
$1.11B
| $147K | ﹤0.01% |
52,160
+9,600
| +23% | +$22.1K |
|
|
TCFC
3881
DELISTED
The Community Financial Corporation Common Stock
TCFC
| $146K | ﹤0.01% |
3,660
| – | – |
|
|
SHOE
3882
Shoe Station Group
SHOE
$413M
| $146K | ﹤0.01% |
6,096
-8,004
| -57% | -$191K |
|
3883
Hurco Companies Inc
HURC
$135M
| $146K | ﹤0.01% |
5,577
| – | – |
|
3884
Entrada Therapeutics
TRDA
$264M
| $146K | ﹤0.01% |
10,772
+9,557
| +787% | +$168K |
|
|
ZYXI
3885
DELISTED
Zynex
ZYXI
| $146K | ﹤0.01% |
10,463
-828
| -7% | -$10K |
|
|
KE
3886
Kimball Electronics
KE
$595M
| $145K | ﹤0.01% |
6,438
+5,369
| +502% | +$115K |
|
3887
Dragonfly Energy
DFLI
$15M
| $145K | ﹤0.01% |
+135
| New | +$128K |
|
|
KLRS
3888
Kalaris Therapeutics
KLRS
$83.5M
| $145K | ﹤0.01% |
1,226
+305
| +33% | +$51.7K |
|
3889
AvePoint
AVPT
$2.76B
| $144K | ﹤0.01% |
35,112
+29,651
| +543% | +$127K |
|
3890
Xeris Biopharma Holdings
XERS
$1.39B
| $144K | ﹤0.01% |
108,311
+47,566
| +78% | +$67.1K |
|
3891
i3 Verticals
IIIV
$412M
| $144K | ﹤0.01% |
5,916
+4,929
| +499% | +$111K |
|
|
GTHX
3892
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $144K | ﹤0.01% |
26,475
-87,156
| -77% | -$730K |
|
3893
Clover Health Investments
CLOV
$2.2B
| $144K | ﹤0.01% |
154,638
+87,349
| +130% | +$117K |
|
3894
PUT
Chevron
CVX
$392B
| $144K | ﹤0.01% |
800
-200
| -20% | -$34.9K |
|
3895
Luxfer Holdings
LXFR
$456M
| $143K | ﹤0.01% |
10,458
+9,005
| +620% | +$131K |
|
3896
Pennant Group
PNTG
$1.4B
| $143K | ﹤0.01% |
13,000
+5,805
| +81% | +$63K |
|
3897
Grupo Cibest SA
CIB
$22B
| $143K | ﹤0.01% |
4,999
| – | – |
|
3898
iShares S&P 100 ETF
OEF
$20.1B
| $142K | ﹤0.01% |
835
-165
| -17% | -$28.5K |
|
|
AFMD
3899
DELISTED
Affimed
AFMD
| $142K | ﹤0.01% |
11,484
+2,162
| +23% | +$37.9K |
|
3900
Oak Valley Bancorp
OVLY
$285M
| $142K | ﹤0.01% |
6,280
-36
| -0.6% | -$707 |
|
Similar funds
Barclays's Q4 2022 Portfolio in Review
As of Q4 2022, Barclays held 5,646 positions worth $223B, up 144% from $91.6B the previous quarter. Its ten largest holdings account for 41% of the portfolio.
Barclays deployed $128B of net new capital in Q4 2022, opening 798 new positions and adding to 2,634 existing holdings. Its largest new stake was Seadrill: 1,546,558 shares worth $50.5M.
By sector, the portfolio is most concentrated in Technology at 12% of assets, down from 23% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $257M trimmed.
- Barclays's largest Q4 2022 buy was Seadrill: 1,546,558 shares worth $50.5M.
- Barclays added most to Microsoft in Q4 2022, an estimated $2.5B increase.
- Barclays's biggest Q4 2022 reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, cutting an estimated $257M.
- Barclays fully exited Citrix Systems Inc in Q4 2022, selling an estimated $913M.
- Barclays's ten largest holdings make up 41% of its $223B portfolio in Q4 2022.
- Barclays opened 798 new positions and closed 385 in Q4 2022.
- Barclays's portfolio value rose 144% quarter-over-quarter to $223B.
Based on Barclays's 13F filing for Q4 2022, filed 13 Feb 2023.